Pharma may not have been the number one priority of late at Bayer AG, with its controversial takeover of Monsanto hogging the headlines, but there are growing concerns about how the German major is going to manage the loss of patent protection on two of its biggest-selling drugs – Xarelto and Eylea.
At the end of last year, Bayer unveiled significant restructuring measures, including a proposed exit from animal health and headcount...








